Dishman Carbogen
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Dishman Carbogen Amcis Limited (DCAL) is navigating a pivotal phase characterized by strategic integration of its manufacturing capabilities and a focus on high-value therapeutic areas. Management's recent commentary highlights optimism stemming from regulatory successes and a robust pipeline of late-phase projects, particularly in oncology, which are expected to drive revenue growth and margin expansion. Vista's financial outlook reflects a cautious stance, anticipating moderating revenue growth and ongoing margin pressure due to competitive pricing dynamics and macroeconomic challenges. However, the company's strategic initiatives, including tech transfers to enhance operational efficiency and a focus on high-margin products, support a long-term growth trajectory. The industry context remains favorable, with increasing demand for diversification in pharmaceutical supply chains and improving pricing power for Indian CDMOs. Over the next 12-24 months, key opportunities include the successful conversion of the project pipeline into commercial supply and the potential for margin recovery through operational efficiencies. Conversely, watchpoints include raw material supply constraints and the impact of regulatory compliance on operational execution
Why We Like This Stock
- Management's focus on high-value oncology projects and successful regulatory approvals is expected to drive future revenue growth
- Strategic tech transfers to India are anticipated to enhance operational efficiency and margin recovery
- The robust pipeline of late-phase projects positions DCAL favorably within the expanding CDMO market
Things To Watch Out For
- Ongoing margin pressure due to competitive pricing dynamics and potential raw material supply constraints
- Short-term revenue growth is moderating, reflecting order deferrals and FX volatility
- Regulatory compliance complexities may pose risks to operational execution and project timelines
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,616 | 2,712 | 2,932 | 2,937 | 3,168 |
| Profit Before Tax (Cr.) | -118 | 36 | 109 | 71 | 86 |
| PBT Margin | -4.5% | 1.3% | 3.7% | 2.4% | 2.7% |
| Net Profit (Cr.) | -174 | -47 | 99 | 66 | 80 |
| Earnings Per Share | -11.1 | -3.0 | 6.3 | 4.2 | 5.1 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.